Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for agalsidase beta

  1. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA915

  2. Migalastat for treating Fabry disease (HST4)

    Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.

    Highly specialised technologies guidance
    Published
    22 February 2017
    View recommendations

    Sections for HST4